案例系列:多克隆静脉注射免疫球蛋白对耐火性Clostridioides difficile感染的有效性
Sophie A Ragan1, Caitlin Doyle2, Neha Datta2
1Department of Gastroenterology, Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK.
Antibodies (Basel, Switzerland)
|April 23, 2024
概括
静脉注射免疫球蛋白 (IVIg) 在治疗耐火性Clostridioides difficile感染 (CDI) 中显示出超过50%的疗效. 数据表明IVIg在患有CDI的免疫抑制患者中可能更有效,这需要进一步调查.
科学领域:
- 传染性疾病 传染性疾病
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 克洛斯特里迪奥伊德困难感染 (CDI) 治疗指南不包括静脉注射免疫球蛋白 (IVIg).
- 一些临床医生仍然使用IVIg治疗严重或复发性CDI (rCDI).
- 调查IVIg疗效和CDI中解决方案的预测因素至关重要.
研究的目的:
- 评估IVIg在患有CDI的患者中的疗效.
- 为了确定IVIg管理后疾病解决的预测因素.
- 探索IVIg在特定患者亚组中的潜在益处.
主要方法:
- 追溯观察队列研究.
- 纳入标准:患有IVIg治疗的严重,复发或rCDI的2岁以上的患者.
- 从英国一家三级医院的电子病例记录中收集的数据 (2018年4月 - 2023年3月).
主要成果:
- 在接受IVIg治疗的20名患者中,有55%的患者表现出疾病缓解 (平均8.6天).
- 在各组之间没有发现解决方案的显著预测因素.
- 一个趋势表明,在免疫抑制患者中,IVIg效应可能会得到增强 (36%的响应者与11%的不响应者).
结论:
- 在耐火性CDI病例中,IVIg治疗在50%以上的病例中实现了疾病的解决.
- 在CDI的免疫抑制个体中,IVIg可能具有增强的效果.
- 需要进一步的病例控制研究和机制研究来澄清IVIg的作用,特别是在免疫抑制患者中.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
160
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
160
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
134
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
134
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Constipation-Predominant IBS
160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160
Drugs for Treatment of Diarrhea-Predominant IBS
161
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
161


